SC issues notice on PIL seeking action against doctors who do not prescribe generic medicines

New Delhi : The Supreme Court on Friday issued notice on a PIL seeking disciplinary actions against doctors who fail to prescribe generic medicines.

A bench comprising Chief Justice of India D.Y. Chandrachud, Justices J.B. Pardiwala and Manoj Misra sought response from the Centre, all state governments, Ethics and Medical Registration Board (erstwhile Medical Council of India) and others in the matter.

Advocate K.C. Jain, the petitioner, apprised the bench that regulations emphasizing the importance of prescribing generic medicines, which were notified back in 2002, remain largely unimplemented in practice.

He said that the Indian Medical Council (Professional Conduct, Etiquette, and Ethics) Regulations, 2002, which highlight the significance of prescribing drugs by their generic names, exist solely within legal frameworks.

The plea said that affordability of medicines is a vital factor that contributes to effective healthcare delivery and the realization of the ‘right to health’.

“Generic drugs, which have the same active ingredients as their branded counterparts but are not marketed under a specific brand name, are often significantly cheaper. The prices of generic medicines (off-patented) can be 50 per cent to 90 per cent lower than those of branded medicines,” stated the petition.

It sought directions to the National Pharmaceuticals Pricing Authority to fix the Maximum Retail Price (MRP) of Non Scheduled formulations and off-patented generic medicines.

“By prescribing generic drugs, healthcare professionals can help alleviate the financial burden on patients and facilitate their access to vital medications,” the plea said.

Related Posts

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

The Maharashtra Food and Drug Administration (FDA) seized 3,098.46 tonnes of food stock worth Rs 63.45 crore and suspended 954 food licences during a statewide enforcement drive in the past…

Stents to syringes: Serious harm reports surge, but makers remain unnamed

6-year data disclosed first time by Indian Pharmacopoeia Commission on CIC order The Indian Pharmacopoeia Commission (IPC) has, for the first time, disclosed the number of Serious Adverse Events (SAEs)…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

Stents to syringes: Serious harm reports surge, but makers remain unnamed

Stents to syringes: Serious harm reports surge, but makers remain unnamed

NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Medicines that cure Us are making Our Environment Sick

Medicines that cure Us are making Our Environment Sick